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Abstract 
Advances in medical care are to a large extent brought forward by new medical technologies. 
Their implementation into daily medical routine requires a careful handling to be of rational use 
for individual patients and to avoid harm as well. For this responsible task critical key questions 
are listed for the deciding medical doctor treating an individual patient, for a conclusive scientific 
evaluation and as a decision support for insurers and policy makers to assess the economic 
potentials and regulatory challenges of new medical technologies and innovations.  
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1. Introduction  
Progress in medical treatment is basically driven by the human genius to search 
for, invent, and recommend new medical technologies after examining pros and 
cons exhaustively. However, the decision to apply non-contractual medical 
technologies is often based on high hopes, core beliefs or principles and / or 
commercial interests. Therefore caution and a critical reluctance are advisable 
before the medical doctor is confident that his patients will actually benefit from 
the new approaches to the treatment. Scientific institutions should have found 
positively evaluated results based on the respective state of the art of medical 
findings and insurances should provide a comprehensive and nationwide 
financing for their insured persons contractually guaranteed.  
 
2. The following Key Questions are 
recommended for 
 
• the medical doctor treating an individual patient (1,2): 
 
 In case of an insured person: Is the designated treatment required by the 
contract or is it non-contractual?  
 Is there a therapeutic consequence for the individual when applying the new 
diagnostic method? 
 Is the relevant diagnosis certain and are the diagnostic prospects exhausted? If 
not, further diagnostic investigations are necessary. 
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 Are there no other methods contractually guaranteed to reach the aims of 
treatment with similar prospects of success? 
 Is there an adequate probability to induce a positive effect on the course of 
disease at the least? 
 Is the evaluation of risks of the new method compared to its advantages 
positively rated for the individual patient? 
 Which are the expected, desired or non desired outcomes applying the new 
method to this particular patient? 
 Is the illness life-threatening with an obviously reduced life expectancy so that 
the state of an emergency occurred to apply the new method as “ultima ratio"?  
 
• the scientific evaluation (1,2): 
 
 Are the effectiveness and risks of the method referring to the indication 
proven by a sufficient number of cases and by applying scientifically correct 
statistics to allow a reliable evaluation?  
 Which is the level of studies according to evidence based medicine (EBM), 
when integrating clinical experience and patient values with the best available 
research information? 
 Which are the results categorizing different types of clinical evidence and 
ranking them according to the strength of their freedom from the various 
biases that beset medical research? Randomized and controlled studies and 
their systematic reviews are usually attributed to the highest value of 
perception. But one has to be careful when transferring the results to 
multimorbid elder people, because they are usually excluded from studies 
which usually concentrate only on one disease or one method. 
 Are there studies performed in several centres, independent from each other, 
confirming the results at the same or differing level of evidence?  
 Is the verification of methodical effectiveness severely impeded? This may be 
the case if diseases are seldom occurring and the etiology and course of the 
disease is not clear. 
 Is there a broad feedback following the discussion of experts? This may be 
documented by the number and quality of publications, publication in peer-
reviewed medical journals, meta-analyses, evaluation of reviews, textbooks, 
guidelines, expert opinions and consensus conferences and editorials.  
Multiple publications authored by the same study group with changing first 
authors do not account for a broad resonance specialist discussion.  
 Is the method applied by a substantial number of medical doctors? 
Epidemiologic health-care data are useful. 
 
• Insurers and Policy Makers to evaluate economic potentials and 
regulatory challenges (1,2): 
 
 Which are the costs for an individual? 
 Which is the cost-benefit ratio for an individual? 
 Which is the cost-benefit ratio for the community of all insured persons? 
 Which is the cost-benefit ratio with regard to the long range impact 
assessment? 
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 Which is the cost-benefit ratio compared to other methods with equal outcome 
effects? 
 Which are the necessary regulations to initiate in case the new method should 
be transferred into routine health care? 
 Which are the necessary regulations to withdraw elder and no longer 
necessary methods from the market or in social health systems from a 
financing through the social health community? 
 Which are the necessary regulations to initiate and secure a sound financing 
and controlling of the insurances` financing? 
 Which are the necessary regulations to sanction medical doctors applying not 
recognized, useless or even harmful new technological methods in the 
treatment of their patients? 
 
An evaluation applying the same method in all cases may not be appropriate for 
any disease, any method of new medical technologies or any issue. It must be 
adjusted to the medical technology itself, the claimed indication and the relevant 
clinical parameters. Furthermore, the evaluation of obtained information that is 
relevant to solve the upcoming questions must be executed sophisticated.  
 
The evaluation is respectively carried out considering the pursued aim of 
treatment on an individual basis or considering the community of all insured 
persons. A critical appraisal of relevant information is needed to find an answer to 
the above mentioned key questions referring to original research articles. 
Abstracts are not sufficient to appreciate the quality of a publication since they do 
not allow the evaluation of the evidence based integrity of the study and its 
results.  
 
Poor evidence leads to poor clinical decisions. Following the above mentioned 
key questions may be helpful to make decisions about the individual and / or 
massive scale application of new medical technologies to the best medical 
knowledge and consciousness. Its goals are to secure the best care quality 
corresponding to the state of the art and to protect patients against commercially 
led, ideologically superimposed or personally guided interests. Orienting towards 
a sound scientific basis and respecting the framework conditions of the varying 
medical care systems may help to optimize the information, cooperation and 
informed consent of patients, medical doctors, insurers, health policy makers and 
lawyers.  
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